DPP4 and kidney disorder: Patients diagnosed with renal disease, coronary heart disease and stroke were 4.20 (p < 0.0001) and 2.22 (p < 0.0001) times more likely to be prescribed DPP-4 inhibitors as first-line outpatient treatment for T2DM.